OncoMatch/Clinical Trials/NCT07027514
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Is NCT07027514 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including tolododekin alfa and Cetrelimab for non small cell lung cancer.
Treatment: tolododekin alfa · Cetrelimab — A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR mutation
Have known EGFR or ALK mutations
Required: ALK mutation
Have known EGFR or ALK mutations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Cannot have received: recombinant interleukin-12
Lab requirements
Cardiac function
baseline electrocardiogram (ECG) without evidence of acute ischemia or prolonged QT interval; no congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or clinically significant cardiac arrhythmias
Have baseline electrocardiogram (ECG) without evidence of acute ischemia or prolonged QT interval; Have congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or clinically significant cardiac arrhythmias [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Community Health Network · Indianapolis, Indiana
- Barbara Ann Karmanos Cancer Hospital · Detroit, Michigan
- Roswell Park Comprehensive Cancer Center · Buffalo, New York
- Icahn School of Medicine at Mount Sinai · New York, New York
- FirstHealth of the Carolinas · Pinehurst, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify